28 results about "Neurological deficit" patented technology

The present invention relates to a system and method configured for analysing acoustic parameters of speech to detect, diagnose, predict and / or monitor progression of a condition, disorder, or disease, and more particularly, any of paediatric and adult neurological and central nervous system conditions including but not limited to low back pain, multiple sclerosis, stroke, seizures, Alzheimer's disease, Parkinson's disease, dementia, motor neuron disease, muscular atrophy, acquired brain injury, cancers involving neurological deficits, paediatric developmental conditions and rare genetic disorders such as spinal muscular atrophy. The system and method extracts a first formant data set from words spoken by an individual and uses these to classify the vowels in the words on a first computing device, such as a mobile smart phone equipped with a microphone into which an individual speaks. The system stores at least some of these frequencies for the vowel formants in a second formant data set as a recorded file and provides the second formant data set as input to acoustic metrics to generate score data from which an assessment is made to determine the articulation level of the vowels in the words spoken by the individual, allowing allow for detection, diagnosis, prediction and / or monitoring progression of the condition, disorder, or disease.

The present invention belongs to the field of biomedical technology and relates to the use of terazosin and (+)-camphor in the preparation of drugs for treating stroke. The research of the present invention shows that the combined use of terazosin and (+)-camphor has a synergistic effect in improving the therapeutic effect of stroke, which can not only significantly improve the neurological deficit symptoms, but also significantly reduce the brain infarction rate, demonstrating a good therapeutic effect on stroke, and thus can be used as a drug for treating stroke.

A method for rehabilitating a patient with neurological deficit or neuromuscular disease, the method including providing a medical walker with an operably connected leg brace, wherein a swing linkage connects the leg brace to the medical walker proximate to a knee of a compromised limb of the patient. The method further includes sensing movement and position in space of the compromised limb of the patient via one or more sensors attached to the leg brace and generating limb data. The method also includes analyzing the limb data, and signaling one or more neuromodulators to activate based at least in part upon analysis of the limb data, wherein the signaling is timed to assist gait motion of the compromised limb.

The application provides a traditional Chinese medicine preparation for treating or improving cerebral hemorrhage and a preparation method thereof, and relates to the technical field of traditional Chinese medicine pharmacy. The traditional Chinese medicine preparation is composed of nacre, antelope horn powder, dragon's blood, Herba Schizonepetae, Prunella vulgaris, Stink-bug, Smilax riparia, bamboo juice, dried tangerine or orange peel, clubmoss, radix puerariae, Zizania aquatica and leaf of Chinese pear. The preparation has a significant therapeutic effect on cerebral hemorrhage, can obviously improve the neurological deficit of cerebral hemorrhage rats, reduce the water content of brain tissue to alleviate brain edema, simultaneously alleviate the inflammatory response in the body, thereby playing a neuroprotective effect on cerebral hemorrhage rats. In addition, the preparation can obviously improve the consciousness state of cerebral hemorrhage patients, alleviate the degree of neurological deficit, relieve the related TCM syndromes of the patients, simultaneously effectively improve the daily life ability of the patients, significantly improve the total effective rate of clinical treatment, and no obvious adverse reactions are observed in the treatment process, and the safety is good, thereby providing a safe and effective treatment scheme for the conservative treatment of cerebral hemorrhage.

The invention provides a traditional Chinese medicine preparation for treating or improving cerebral hemorrhage and a preparation method thereof, and relates to the technical field of traditional Chinese medicine pharmacy, the traditional Chinese medicine preparation is composed of nacre mother of pearl, antelope horn powder, dragon's blood, motherwort fruit, selfheal, aspongopus, radix actinidiae chinensis, bamboo juice, pericarpium citri reticulatae, selaginella tamariscina, radix puerariae, zizania aquatica and folium eriobotryae. The traditional Chinese medicine composition can obviously improve neurological impairment of cerebral hemorrhage rats, reduce the water content of brain tissues to relieve encephaledema and reduce inflammatory response in vivo, thereby playing a role in protecting the nerves of the cerebral hemorrhage rats. Besides, the preparation can obviously improve the consciousness state of a cerebral hemorrhage patient, relieve the degree of neurological impairment, relieve related traditional Chinese medicine syndromes of the patient, effectively improve the daily living ability of the patient and obviously improve the total effective rate of clinical treatment, no obvious adverse reaction is observed in the treatment process, and the preparation is good in safety and free of toxic and side effects. And a safe and effective treatment scheme is provided for the conservative treatment of cerebral hemorrhage.

The present invention provides the use of α-asarone in the preparation of a drug for preventing or treating hemorrhagic stroke. The structure of α-asarone is shown in Formula I. It can significantly improve short-term neurological deficits and long-term learning and memory function in model rats, reduce cerebral edema, improve blood-brain barrier permeability, and prevent or alleviate brain tissue atrophy during the recovery period. It has a definite therapeutic effect on animal models of hemorrhagic stroke without significant toxic side effects, and is expected to become a promising drug for the prevention and treatment of hemorrhagic stroke. #imgabs0#

An automated and quantitative facial weakness screening framework that utilizes a Bi-LSTM network to model the temporal dynamics among the shape and appearance features. The technique is beneficial to assist the paramedics or other users to identify the facial weakness in the field or, more importantly, whenever expertise in neurology is not available either for emergency patient triage (e.g., pre-hospital stroke care) or chronic disease management (e.g., Bell's palsy rehabilitation screen), leading to increased coverage and earlier treatment. The technique provides visualizable and interpretable results to increase its transparency and interpretability. The technique provides for inexpensive solutions that can be used in areas underserved by non-neurologists to more readily identify neurological deficits such as facial weakness in the field or other environment.

The invention belongs to the technical field of biological medicine, and particularly relates to a nano-micelle preparation loaded with minocycline and application of the nano-micelle preparation to treatment of cerebral hemorrhage, the nano-micelle preparation is prepared by taking a polyethylene glycol-polycaprolactone nano material PEG3000-PCL2000 as a carrier, and jointly loading minocycline MINO and a CD147 monoclonal antibody Anti-CD147, so that the nano-micelle preparation is prepared. And the bionic nano-drug MINO (at) PNM (at) CD147 with an active targeting function is constructed. The nano-micelle preparation has a brain targeting property and can be enriched in cerebral hemorrhage tissues, so that the local drug concentration and the treatment efficiency are remarkably improved; the traditional Chinese medicine composition can improve neurological impairment caused by cerebral hemorrhage and significantly reduce the volume of cerebral hematoma, and has an obvious treatment effect on cerebral hemorrhage; the number of inflammatory cells in the peripheral area of hematoma and expression of inflammatory mediators can be remarkably reduced, and therefore the inflammatory response in cerebral hemorrhage tissue is relieved.

Aspects are directed to providing or administering novel therapeutic combinations for the treatment of tauopathies such as AD and other neurological deficiencies or dementias. Certain aspects include methods of using two or more drugs selected from an immunomodulator (IMD), antiviral (AVT), and magnesium (Mg) for the treatment of AD and / or other tauopathies; or compositions containing two or more drugs selected from an immunomodulator (IMD), antiviral (AVT), and magnesium (Mg).

The present application relates to the technical field of medicine, especially relates to application of a small molecule compound LZ-09 in preparation of a medicine for treating and / or preventing multiple sclerosis. The present application adopts H2O2 damage OLN-93 cells as a nerve cell oxidative stress model, and the result shows that LZ-09 treatment significantly weakens the cell viability decrease caused by H2O2. The classic EAE model is made by using MOG35-55 to induce C57BL / 6 mice, and it is found that after LZ-09 intervention, the mouse neurological deficit symptom score is significantly reduced, and the disease progression is delayed, and spinal cord tissue HE and LFB staining find that the inflammation infiltration and demyelination are reduced. Therefore, the compound can effectively alleviate the symptoms of multiple sclerosis, can be used as a medicine for treating multiple sclerosis, and has wide development and application prospect.

Provided in the present invention is use of bremelanotide in the preparation of a drug for preventing and / or treating ischemic stroke. Bremelanotide can ameliorate neurological deficits, reduce the cerebral infarction area, and improve the cerebral blood flow in ischemic stroke.

The invention belongs to the technical field of biology, and particularly discloses application of an umbilical cord mesenchymal stem cell combined exosome in treatment of neurological function deficiency after brain injury, a tangential flow filtration method and a precipitation method are combined for extraction of an ultrapure exosome, and the umbilical cord mesenchymal stem cell and the exosome are combined for use, so that the survival rate of brain injury cells is increased, and the neurological function deficiency after brain injury is treated. According to the application, the secretion level of an inflammatory factor TNF-alpha is reduced, and meanwhile, the expression of a neurotrophic factor NGF is promoted, so that the repair and improvement of the neurological function after the brain injury are realized, and the application can be used for treating the neurological function deficiency after the brain injury. Compared with a traditional treatment method, the umbilical cord mesenchymal stem cells and the exosome are combined for use, so that the neurological function deficiency can be more effectively improved, the inflammatory response is relieved, the neural restoration is promoted, and a new thought and a new method are provided for clinical treatment of brain injury patients.

This invention provides a composite composition containing nervonic acid and its use in brain nerve repair, belonging to the field of biotechnology. The invention uses nervonic acid and phosphatidylserine, combined with plant extracts fermented by a microbial concoction of *Lactobacillus acidophilus*: *Lactobacillus rhamnosus*: *Bacillus belyssae* = (2-3):1:1, to form a composite composition. This scientific formulation achieves synergistic effects from multiple components, improving neurological deficits, reducing cerebral infarction volume, decreasing the release of neurotrophic markers, and upregulating neurotrophic factor expression through multi-target synergistic effects. Furthermore, this synergistic effect depends on specific component ratios, providing crucial experimental support for the development of subsequent brain-protective functional compositions. This composition can be widely applied to the preparation of brain nerve repair drugs, functional foods, and dietary supplements, possessing promising industrialization prospects and clinical value.

The present invention relates to stable, sterile, ready-to-use aqueous pharmaceutical formulation comprising nimodipine or its pharmaceutically acceptable salts, and pharmaceutically acceptable excipients. The present invention also relates to a stable, sterile, ready-to-use aqueous pharmaceutical formulation comprising nimodipine containing no more than about 0.41% w / v of nitroso impurity and no more than about 0.41% w / v of di-isopropyl impurity. The formulation is suitable for parenteral administration and is provided in a suitable container. The invention further relates to method of manufacture and sterilization of such formulations and using the formulation for prophylaxis and treatment of ischemic neurological deficits caused by cerebral vasospasm following subarachnoid hemorrhage of aneurysmal origin.

The present invention relates to the field of treat age-related cognitive declines. In this study, the inventors report that GPR158, which localizes at the PC, is required for OCN- dependent autophagy induction in hippocampal neurons. Consistently, the mobilization of key autophagy players by OCN in hippocampal neurons requires core PC-proteins. In aged hippocampi, neuronal PC present an abnormal morphology, correlated with a reduction of the major core ciliary proteins levels. Conversely, restoration of their levels in aged hippocampi is sufficient to improve autophagy and cognitive deficits. Lastly, they show that core PC-proteins are required to integrate the rejuvenating effects of OCN in the hippocampus, thereby ameliorating age-related cognitive deficits. Altogether, these findings demonstrate a new paradigm for the neuron / systemic milieu communication and significantly advance our understanding of the regulatory mechanism mediating the rejuvenating effects of the pro-youth blood factor, OCN, in hippocampal neurons. This study also provides the foundation for novel therapeutic strategies to treat age-related cognitive decline, as well as neurological deficits in ciliopathies. Thus, the present invention relates to an activator of the primary cilia (PC) for use in the restoration and / or improvement of cognitive functions in a subject in need thereof.

This invention discloses a traditional Chinese medicine composition for treating cerebrovascular diseases, belonging to the technical field of cerebrovascular disease drugs. The composition comprises the following components in parts by weight: 10-30 parts of Polygonatum sibiricum, 6-15 parts of Rosa laevigata, 6-12 parts of Euonymus alatus, 6-15 parts of Polygonum cuspidatum, 3-9 parts of Acorus tatarinowii, 3-10 parts of Alpinia oxyphylla, 3-6 parts of Aralia elata septum, 3-10 parts of Rhodiola rosea, 3-10 parts of Bletilla striata, and 1-6 parts of Cinnamomum cassia. This invention addresses the pathological characteristics of cerebrovascular diseases, including long disease courses, multiple risk factors, and involvement of multiple target organs. Through the systematic combination of ten herbs, it can simultaneously achieve cerebrovascular protection, nerve function repair, and protection against multi-organ damage. Animal experiments and clinical observations have confirmed that this composition can significantly improve patients' neurological deficit scores, reduce the incidence of complications, and has clear preventive and therapeutic effects on secondary complications such as stress ulcers and renal impairment, while also possessing antithrombotic and hemostatic properties and high safety.

The invention discloses application of LARP7 in diagnosis and treatment of cerebral arterial thrombosis. The research finds that the LARP7 content in serum and cerebrospinal fluid of a clinical cerebral arterial thrombosis patient is obviously higher than that in healthy people, the ROC curve finds that the LARP7 has higher diagnosis efficiency on cerebral arterial thrombosis, has the advantages of high accuracy, good specificity, high sensitivity and the like, and can be used as a new biomarker for diagnosis of cerebral arterial thrombosis. Further animal experiments find that the serum LARP7 of the mouse suffering from cerebral ischemia reperfusion injury is also obviously increased and reaches a peak on the third day after reperfusion. The overexpression of the LARP7 can relieve neurological function defects of mice suffering from cerebral ischemia injury and reperfusion injury and reduce the volume of cerebral infarction, which prompts that the LARP7 can be used as a potential target for clinical treatment of cerebral arterial thrombosis. The invention provides a new biomarker deterioration treatment target for early diagnosis of cerebral arterial thrombosis.

The present invention provides an application of α-asarone in the preparation of a medicine for preventing or treating hemorrhagic strokes. α-asarone has the structure shown in formula I, and may significantly improve short-term neurological deficits and long-term learning and memory functions of model rats, reduce cerebral edema, improve the permeability of the blood-brain barrier, and prevent or mitigate the atrophy of brain tissue during a recovery period. α-asarone has a precise therapeutic effect on animal models of hemorrhagic stroke without obvious toxic side effects, and is expected to have great application prospects as a medicine for preventing / treating hemorrhagic strokes.

FIELD: neurosurgery and neurology.SUBSTANCE: after surgical access, a vessel located on the surface of the tumor tissue and extending into adjacent areas of the cortex is visualized. On both sides of the vessel, a bipolar electrode is used to coagulate the areas of the cortex affected by the tumor. Then, using microscissors, the arachnoid membrane is opened in the area of coagulation zones. An encephalotomy is performed. Next, subpial resection of the tumor in these areas is performed using an ultrasonic destroyer-aspirator, preserving the arachnoid membrane in which the preserved vessel passes. When visualizing a vessel located deep in the groove, dissection of the groove is performed while preserving the arachnoid membrane in which the vessel passes. The tumor around the vessel is resected using an ultrasonic destroyer-aspirator. In this case, first the part of the tumor on one side of the vessel is resected, then the part on the other side. These resection areas are connected to each other under the vessel. Then the residual tumor fragments on the vessel are removed. When visualizing a vessel passing through a tumor to healthy areas of the brain, this vessel is preserved, and the tumor tissue is separated from it along the periphery using an ultrasonic destroyer-aspirator. During the isolation of cortical and subcortical vessels, they are irrigated with saline solution. Then, through the resulting “intervascular windows,” deeply located tumor fragments are removed.EFFECT: method allows for the preservation of blood flow in cortical vessels during the removal of glial brain tumors, reducing the risk of developing ischemic complications in functionally significant areas of the cortex adjacent to the tumor resection zone, as well as in the subcortical structures of the brain, which, as a consequence, is associated with lower risks of developing postoperative neurological deficit.1 cl, 3 ex

The application discloses application of CADM3 in preparation of products for treating autoimmune diseases, belongs to the technical field of biological medicine, and the amino acid sequence of the CADM3 is shown as SEQ ID NO.2.The application discloses that CADM3 is up-regulated on the surface of activated APC, in vitro cell intervention experiments are carried out by using prepared hCADM3-Ig fusion protein, it is confirmed that the fusion protein can effectively block the activation and proliferation of T cells, and further regulate the overactive autoimmune response.Through animal experiment verification, compared with the control group, the hCADM3-Ig fusion protein treatment group can significantly improve the neurological deficit symptoms of EAE model mice, obviously reduce the intestinal dysfunction of IBD model mice, effectively reduce the degree of inflammatory reaction in the two models, and significantly inhibit the activation and proliferation of pathological T cells.

The invention relates to the field of medical information processing, in particular to a stroke home rehabilitation guidance method and system based on multi-dimensional classification. The method comprises the following steps: acquiring basic conditions of a stroke patient, and classifying disease characteristics, neurological function defect parts, severity and complications to form a classification result; executing patient group mapping based on a classification result, and establishing corresponding key monitoring related indexes; change collection and change analysis are carried out according to key monitoring related indexes, and stage rehabilitation scheme suggestions are generated; and carrying out abnormal judgment and online guidance according to the stage rehabilitation scheme suggestions, forming adjustment suggestions, and writing back the adjustment suggestions. According to the invention, the classification result is used as an organization basis throughout the whole process, so that a consistent closed-loop processing link is formed by monitoring, analysis, guidance and write-back, and the continuity, traceability and collaborative stability of the scheme generation and adjustment process in the stroke home rehabilitation guidance process are improved.

This invention discloses a material-empowered stem cell-derived exosome, its preparation method, and its application, belonging to the field of biomedical technology. The method involves the following steps: mesenchymal stem cells are seeded onto a substrate fused with N / VE-cadherin-Fc fusion protein and cultured to assemble into aggregates; the aggregates are dynamically cultured under staged shear stress; the culture medium is collected, and the exosomes are separated and purified. The preparation method of this invention overcomes the shortcomings of existing mesenchymal stem cell exosome preparation technologies, such as low yield and insufficient neurovascular repair function. It significantly activates exosome biogenesis-related molecular pathways, increases exosome yield by approximately four times, and is rich in miRNAs related to neurovascular repair. It can significantly improve neurological deficits in stroke mice and hindlimb motor function in rats with spinal cord injury, providing a highly efficient and stable cell-free therapeutic strategy for the treatment of central nervous system injuries.

The invention discloses application of CADM3 in preparation of a product for treating autoimmune diseases, and belongs to the technical field of biological medicines, and the amino acid sequence of the CADM3 is shown as SEQ ID NO.2. The expression of CADM3 on the surface of activated APC is up-regulated, an in-vitro cell intervention experiment is carried out by using the prepared hCADM3-Ig fusion protein, and it is proved that the fusion protein can effectively block activation and proliferation of T cells, and then over-active autoimmune response is regulated and controlled. Animal experiments prove that compared with a control group, an hCADM3-Ig fusion protein treatment group can remarkably improve the neurological function defect symptom of an EAE model mouse, remarkably relieve intestinal dysfunction of an IBD model mouse, effectively reduce the inflammatory reaction degree in the two models and remarkably inhibit activation and proliferation of pathological T cells.

This invention belongs to the field of biomedicine, specifically disclosing the use of a combination of Panax notoginseng total saponins and chemical drugs as effective components in the preparation of drugs for the prevention and treatment of stroke. Experiments have shown that the combination of Panax notoginseng total saponins and chemical drugs can effectively improve neurological deficits, significantly reduce the incidence of combined cardiovascular and cerebrovascular events within one year, and further significantly reduce the incidence of combined cardiovascular and cerebrovascular events in long-term follow-ups of 2 and 3 years. Therefore, the combination of Panax notoginseng total saponins and chemical drugs can be used for the prevention of combined cardiovascular and cerebrovascular events in stroke patients, with good efficacy and safety.

Methods and apparatuses for sensory electrical stimulation of the peripheral nervous system to improve human motor function and performance are described. Methods and devices may be used to enhance physical performance of athletes, professionals, and gamers or improve motor function (hand, finger and limb movement) in patients rehabilitating from neurological deficits and impairments caused by stroke, traumatic brain injury and other neurologic or non-neurologic conditions. These apparatuses and methods may be used for physical training and mental training (to improve memory and functional performance including motor coordination, limb-eye coordination, occupational and recreational skills) through periodic or sustained sensory electrical stimulation. Treatment plans may be based on biomarkers and may be used alone or in combination with other apparatuses. Learning and feedback techniques individualize treatment parameters depending on the subject's neurologic and motor function in diseased patients and healthy users.

The present invention provides a drug for preventing and treating ischemic stroke, which belongs to the field of neuromedicine technology. The drug comprises a salmon polypeptide as shown in SEQ ID NO.1 and a pharmaceutically acceptable carrier. Experimental results show that the salmon polypeptide has good safety, can effectively improve brain cell oxygen-glucose deprivation / reoxygenation damage, and significantly reduce neurological deficits and cerebral infarction in ischemic stroke mice. The present invention also discloses a pharmaceutical composition for treating ischemic stroke, comprising salmon polypeptide and edaravone. The composition exhibits a significant synergistic effect, and can more significantly reduce neurological deficits and cerebral infarction compared to the use of salmon polypeptide or edaravone alone, and the actual effect is significantly better than the theoretical superposition effect. Therefore, the present invention provides a new and more effective treatment option for the treatment of ischemic stroke.

This invention relates to the field of pharmaceutical technology, specifically to a perioperative neuroprotective anesthetic composition and its application for ischemic stroke. The composition comprises the active ingredient remimazolam or a pharmaceutically acceptable salt thereof, MCC950, TRO19622, levamisole or a pharmaceutically acceptable salt thereof, lipoic acid, and a pharmaceutically acceptable carrier, with each active ingredient formulated in a specific molar ratio. This composition combines stable and controllable anesthetic effects with multi-target synergistic neuroprotective effects, adapting to the entire perioperative anesthesia needs for ischemic stroke. Through upstream and downstream synergistic inhibition of mitochondrial damage and the NLRP3 pyroptosis pathway, dual regulation of perioperative sympathetic tone to stabilize cerebral perfusion, synergistic reduction of glutamate excitotoxicity, and enhancement of endogenous antioxidant defense, it comprehensively blocks the core links of perioperative ischemia-reperfusion brain injury, significantly reducing the risk of postoperative neurological deficits and cognitive impairment. It exhibits excellent circulatory and respiratory safety, rapid awakening without affecting early postoperative neurological function assessment.

The invention discloses an intracranial aspiration catheter which comprises a first catheter body, a second catheter body, a diffusion stress tube and a catheter base which are sequentially communicated in series from the far end to the near end. The pipe diameter of the first pipe body is reduced in a stepped manner from the far end to the near end; the first pipe body comprises a first straight section, at least one second straight section and at least one guide pipe transition section; wherein the far end of the second pipe body is communicated with the adjacent corresponding second straight section, and the end, away from the second pipe body, of the second straight section is communicated to the next-stage second straight section or the first straight section with the smaller pipe diameter through the catheter transition section; the elasticity modulus of the first tube body and the elasticity modulus of the second tube body are gradually reduced in the axial direction from the near end to the far end. Therefore, the problem of vascular occlusion in a medium-diameter vascular area can be effectively solved, vascular path injury is avoided, an occluded section can be quickly and conveniently reached, the blood vessel is dredged, and serious neurological function defects caused by occlusion are reduced.